Process for t cell expansion
AssigneesAlloVir, Inc., Baylor College of Medicine, Wilson Wolf Manufacturing
InventorsRainer Ludwig Knaus, Katy Rebecca Newton, Juan Vera, Ann Leen, Cliona Rooney, John R. Wilson
Life of this patent
Estimating the term…
Loading patent…
AssigneesAlloVir, Inc., Baylor College of Medicine, Wilson Wolf Manufacturing
InventorsRainer Ludwig Knaus, Katy Rebecca Newton, Juan Vera, Ann Leen, Cliona Rooney, John R. Wilson
Estimating the term…
An in vitro expansion process for rapid expansion of antigen specific T cells, such as allogeneic antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs (such as allogeneic PBMCs) in the presence of antigen, for example a peptide or peptide mix relevant to a target antigen(s), in the presence of an exogenous cytokine characterized in that the expansion to provide the desired population of T cells is 14 days or less, or example 9, 10, 11 or 12 days, such as 10 days. The disclosure also extends to T cell populations generated by and obtained from the method and the use of same in therapy.
An antigen-specific T cell population (such as an allogeneic antigen specific T cell population) obtained or obtainable from a process for rapid expansion of antigen specific T cells comprising the steps culturing in a gas permeable vessel a population of PBMCs in the presence of a peptide or peptide mix relevant to a target antigen(s) in the presence or an exogenous cytokine characterized in that the cytokine is other than exogenous IL-2.
A pharmaceutical composition of an expanded antigen specific T cell population for a patient, wherein the composition comprises:
Dependencies are inferred from the claim text.